Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studies

被引:3
作者
Kamimura, Tomohiro [1 ]
Hounslow, Neil [2 ]
Suganami, Hideki [3 ]
Tanigawa, Ryohei [4 ]
机构
[1] Kowa Co Ltd, Med Affairs Depr 1, 4-10 Nihonbashi honcho 3 chome,Chuo-ku, Tokyo 1030023, Japan
[2] Kowa Pharmaceut Europe Co Ltd, Wokingham, England
[3] Kowa Co Ltd, Global Data Sci Ctr, Tokyo, Japan
[4] Kowa Co Ltd, Global Clin Dev Dept, Tokyo, Japan
来源
CTS-CLINICAL AND TRANSLATIONAL SCIENCE | 2024年 / 17卷 / 08期
关键词
PROLIFERATOR-ACTIVATED RECEPTOR; PPAR-ALPHA MODULATOR; DOUBLE-BLIND; CARDIOVASCULAR-DISEASE; SPPARM-ALPHA; SAFETY; K-877; SIMVASTATIN; EFFICACY; METABOLISM;
D O I
10.1111/cts.13900
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Elevated triglyceride levels are associated with an increased risk of cardiovascular events despite guideline-based statin treatment of low-density lipoprotein cholesterol. Peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists exert a significant triglyceride-lowering effect. However, combination therapy of PPAR alpha agonists with statins poses an increased risk of rhabdomyolysis, which is rare but a major concern of the combination therapy. Pharmacokinetic interaction is suspected to be a contributing factor to the risk. To examine the potential for combination therapy with the selective PPAR alpha modulator (SPPARM alpha) pemafibrate and statins, drug-drug interaction studies were conducted with open-label, randomized, 6-sequence, 3-period crossover designs for the combination of pemafibrate 0.2 mg twice daily and each of 6 statins once daily: pitavastatin 4 mg/day (n = 18), atorvastatin 20 mg/day (n = 18), rosuvastatin 20 mg/day (n = 29), pravastatin 20 mg/day (n = 18), simvastatin 20 mg/day (n = 20), and fluvastatin 60 mg/day (n = 19), involving healthy male volunteers. The pharmacokinetic parameters of pemafibrate and each of the statins were similar regardless of coadministration. There was neither an effect on the systemic exposure of pemafibrate nor a clinically important increase in the systemic exposure of any of the statins on the coadministration although the systemic exposure of simvastatin was reduced by about 15% and its open acid form by about 60%. The HMG-CoA reductase inhibitory activity in plasma samples from the simvastatin and pemafibrate combination group was about 70% of that in the simvastatin alone group. In conclusion, pemafibrate did not increase the systemic exposure of statins, and vice versa, in healthy male volunteers.
引用
收藏
页数:12
相关论文
共 40 条
[1]  
[Anonymous], Lochol tablets Fluvastatin
[2]  
[Anonymous], Bezatol SR tablets Bezafibrate
[3]  
[Anonymous], Lopid Gemfibrozil tablet, film coated
[4]  
[Anonymous], Lipantil Micro 200 mg capsules fenofibrate
[5]  
[Anonymous], Tricor tablets Fenofibrate
[6]  
[Anonymous], Livalo tablets Pitavastatin
[7]  
[Anonymous], Lipitor tablets Atorvastatin
[8]  
[Anonymous], TRICOR Fenofibrate tablet
[9]  
[Anonymous], Crestor tablets Rosuvastatin
[10]  
[Anonymous], Parmodia Tablets Pemafibrate